CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Nonprofits' gene therapy for rare immune disease will cost $3.25 million

RegulatoryapprovedWaskyraPositive
AI Analysis

Summary

Two nonprofits launched Waskyra, a gene therapy for rare immune disease previously approved by FDA, at a list price of $3.25 million.

Outcome Details

FDA approval received at end of last year

Importance:6/10
Sentiment:
0.60
gene therapyrare diseaseFDA approvalpricingnonprofit

Read the original article

Published by Endpoints News on September 28, 2026 3:45 PM

Read Original